2024
Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource
Ito S, Pandya A, Hauser R, Krishnamurti L, Stites E, Tormey C, Krumholz H, Hendrickson J, Goshua G. Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource. American Journal Of Hematology 2024, 99: 570-576. PMID: 38279581, DOI: 10.1002/ajh.27211.Peer-Reviewed Original ResearchSickle cell diseaseDelayed hemolytic transfusion reactionQuality-adjusted life expectancyAlloimmunized patientsPatient populationRed blood cell alloimmunizationCell diseaseCost-effective interventionMedical expenditure of patientsHealth system perspectiveExpenditure of patientsIncremental cost-effectiveness ratioHemolytic transfusion reactionsUnited StatesMarkov cohort simulationCost-effectiveAverage patient populationCost-effectiveness ratioBirth cohortAnalytical time horizonAntibody historyCohort simulationTransfusionTransfusion reactionsLife expectancy
1993
Cost-effectiveness of a smoking cessation program after myocardial infarction
Krumholz H, Cohen B, Tsevat J, Pasternak R, Weinstein M. Cost-effectiveness of a smoking cessation program after myocardial infarction. Journal Of The American College Of Cardiology 1993, 22: 1697-1702. PMID: 8227841, DOI: 10.1016/0735-1097(93)90598-u.Peer-Reviewed Original ResearchConceptsSmoking cessation programAcute myocardial infarctionNurse-managed smoking cessation programCessation programsMyocardial infarctionYears of lifeBeta-adrenergic antagonist therapyLife expectancyOne-way sensitivity analysesTwo-way sensitivity analysesCost-effective interventionHealth care resourcesAntagonist therapySmoking ratesInfarctionCare resourcesSmokersInterventionProgram costsYearsExpectancyTherapyLife